Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia

Choi, Jae Duck; Kim, Jung Hoon; Ahn, Seung Hyun

doi:10.1159/000442995

Cited by 13 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet another study reported a strong correlation when the cut-off value for TZI was 0.50 (6). The same cut-off for TZI, 0.50, was also confirmed in the most recent study (21). Our cut-off values 0.40 and 0.45 are in line with the above-cited studies.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia

Kirkali¹

2016

jus

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? ÖZ ObjectiveThe objective of this study was to determine the role of the transition zone (TZ) index (TZI) in the prediction of clinical benign prostatic hyperplasia (BPH) in patients who underwent transurethral prostatectomy (TUR-P) and to analyze the correlation between the amount of resected tissue and TZ volume (TZV). Materials and MethodsTwenty-six male clinical BPH patients with obstructive complaints and 17 male benign prostate enlargement (BPE) patients without any complaints were included in the study. Both the groups were over the age of 50. Clinical BPH patients underwent complete TUR-P. Statistical analysis was done with SPSS. Sensitivity, specificity, positive and negative predictive values of TZI-as a method of assessing clinical BPH-were measured.

show abstract

Section: Discussionsupporting

confidence: 91%

“…There is one more recent study on the same subject. In this study, it is reported that TZI ≥0.50 has a strong correlation with MFR improvement (21).…”

Section: Discussionmentioning

confidence: 60%

Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia

Kirkali¹

2016

jus

View full text Add to dashboard Cite

show abstract

“…No significant differences were found in terms of Hb, Hct, MVD, and VEGF in prostates of <50 mL. Thus, the prostate volume and even the transition zone index [35] should be taken into account before decision making. There are also some surgical alternatives to medication.…”

Section: Discussionmentioning

confidence: 95%

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

Ren

Lai²,

Jiang³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Objective: This systematic review and meta-analysis were performed to evaluate the efficacy of preoperative dutasteride treatment for reducing surgical blood loss in patients undergoing transurethral resection of the prostate (TURP). Methods: A systematic search was performed from the electronic databases including PubMed, EMBASE, and Cochrane Library by May 2016. We followed the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis statement when examining the literature. Identified articles were strictly appraised for quality and relevance. Results: Five randomized controlled trials (RCTs) and 5 retrospective cohort studies involving 1,022 patients with benign prostate hyperplasia were analyzed based on the inclusion criteria. Pooled analysis revealed that preoperative treatment with dutasteride had a significantly smaller decrease in hemoglobin (weighted mean difference [WMD] -0.47, 95% CI -0.70 to -0.24, p < 0.0001) and hematocrit levels (WMD -1.03, 95% CI -1.73 to -0.33, p = 0.004); However, no signiﬁcant difference has been found in terms of the total blood loss during TURP and blood loos per gram of resected prostatic tissue, the weight of resected prostate tissue, the microvessel density of the prostate, and the transfusion rate between the dutasteride and the control group. Conclusions: This systematic review and meta-analysis indicate that preoperative treatment with dutasteride could reduce surgical bleeding during TURP, but the findings of this study should be further confirmed by well-designed prospective RCTs with a larger patient series.

show abstract

“…Pharmacotherapy based on polytherapy used solifenacin and tamsulosin also communicated with progress in patient detailed outcomes such as urinary nerve growth factor and creatinine levels (23). Investigation of Choi et al (24) showed that combination therapy comprising of α-blockers and 5α-reductase inhibitors in patients with a transitional zone index (TZI) of ≥ 0.5 is expected improvement linked to greater maximum urinary flow rates (Qmax). As a final point according to the published articles tamsulosin-therapy based on inter-and intra-individual assumption for BPH, seem to be safe and effective to improve the related symptoms and quality of life in patients.…”

Section: Resultsmentioning

confidence: 99%

A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia

Ghamari

Mazdak

2016

Jundishapur J Chronic Dis Care

View full text Add to dashboard Cite

Context: Benign prostatic hyperplasia (BPH) that disturbs aged males is described as the abundant, chronic progressive disorder usually associated with lower urinary tract symptoms. The alpha 1A-adrenergic receptor antagonist, tamsulosin (Flomax®/Omnic®), seems to be an appropriate management from the view point of urological surgeons. The current review aimed to evaluate the clinical pharmacological properties of tamsulosin in prostate disorders. Evidence Acquisition: United States national library of medicine (PubMed, NLM) were searched from April 1991 to March 2016. The Mesh terms were: tamsulosin, tamsulosin pharmacokinetics in urology, tamsulosin in BPH and clinical pharmacokinetics of tamsulosin in BPH. Published clinical trials and review articles applicable to pharmacotherapy of tamsulosin in BPH were reviewed. Results: In patients with mild international prostate symptom score (< 8) to moderate symptoms of BPH, initial treatment with an alpha 1-adrenergic antagonist monotherapy were useful. With a half-life of 9 -13 hours, the oral bioavailability of drug was reported 100%. The drug is metabolized by liver. Excretion through renal was reported 76%. Initial dose of drug was 0.4 mg/day and the maximum dose was reported 0.8 mg/day. The drug could cause dizziness, sever drowsiness and problems in thinking, driving and many other complications. Other serious adverse reactions could be mentioned as hives, rash, itching, and difficulty in breathing, swelling of face, lips, tongue and throat. Tamsulosin therapy should be stopped in patients who experience hypotension. Conclusions: To treat BPH therapeutically, it is necessary to stabilize severities of the patient's symptoms with potential side effects of the treatment. Tamsulosin blocks alpha 1-receptors in smooth muscles both in the bladder neck and prostate, which leads to relaxation and subsequently less resistance to urinary flow. By advancement of tamsulosin, pharmacotherapy strategies could provide more appropriate guideline treatments; therefore, in Isfahan, Iran, innovative medical treatment for BPH was suggested based on both pharmacological and surgical clinical trials.

show abstract

Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia

Cited by 13 publications

References 23 publications

Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia

Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia

A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate

A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About